Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease

Saved in:

Bibliographic Details
Main Authors:	Doaa H. Hegazy, Fathalla S. Mohamed, Sabah A. H. Mahmoud, Nevine M. F. El Deeb, Amany Elyamany, Ahmed M. Elgendi
Format:	Article
Language:	English
Published:	Termedia Publishing House 2024-06-01
Series:	Clinical & Experimental Hepatology
Subjects:	metabolic associated steatotic liver disease non-alcoholic fatty liver disease activity score macrophage kupffer cells
Online Access:	https://www.termedia.pl/Liver-macrophage-activation-Relation-with-hepatic-histopathological-changes-in-patients-with-metabolic-associated-steatotic-liver-disease,80,54195,1,1.html
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01)

Treatment of HCV infection in patients with steatotic liver disease
by: Robert Flisiak, et al.
Published: (2024-07-01)

The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease
by: Anna E. Płatek, et al.
Published: (2023-09-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
by: Sebastian Holländer, et al.
Published: (2025-01-01)

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study
by: Hui Liu, et al.
Published: (2025-01-01)

Histopathological analysis of the liver in hypercholesterolemia rats treated with Dillenia serrata fruits
by: Tien, et al.
Published: (2022-12-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01)

From gut to liver: Exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease
by: Mi Zhou, et al.
Published: (2025-01-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)

Effect of a Ketogenic Diet on Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Progression: A Randomized Controlled Trial
by: Sakkarin Chirapongsathorn, et al.
Published: (2025-01-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk
by: Núria Granel, et al.
Published: (2025-02-01)

Recent trends in studying of alcohol-induced liver disease
by: I. I. Komkova, et al.
Published: (2011-12-01)

Uric acid as a potential marker of cardiometabolic risk in children and adolescents with metabolic dysfunction associated steatotic liver disease
by: Katarzyna Zdanowicz, et al.
Published: (2024-09-01)

Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

The Liver X Receptor Promotes Immune Homeostasis via Controlled Activation of the Innate Immune System in the Liver
by: Hiroyuki Nakashima, et al.
Published: (2024-12-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease
by: Farshad Amirkhizi, et al.
Published: (2025-01-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

Dose-response relationship between the fatty liver index and asthma risk: NHANES 2001~2018
by: Tengfei Sun, et al.
Published: (2025-02-01)

Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States
by: Fan Zhang, et al.
Published: (2025-01-01)

Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment
by: Ye. N. Shirokova
Published: (2023-08-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Lachnospiraceae-bacterium alleviates ischemia-reperfusion injury in steatotic donor liver by inhibiting ferroptosis via the Foxo3-Alox15 signaling pathway
by: Shenghe Deng, et al.
Published: (2025-12-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01)

Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
by: Hongcai Li, et al.
Published: (2025-02-01)

Association between non-alcoholic fatty liver disease and progression of abdominal aortic aneurysm: a multicenter study
by: Ximing Wang, et al.
Published: (2025-01-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China
by: Guanghui Ma, et al.
Published: (2025-01-01)

The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates
by: Ruike Yan, et al.
Published: (2025-01-01)

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: A. E. Bagriy, et al.
Published: (2021-06-01)

Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
by: Kangjie li, et al.
Published: (2025-03-01)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease
by: V. T. Ivashkin, et al.
Published: (2022-12-01)

Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study
by: Nan Li, et al.
Published: (2025-01-01)